ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.060,08
-0,40%
S&P 500
5.116,17
0,32%
Dow Jones
38.386,09
0,00%
Euro vs US Dollar
1,07237
0,08%
Bitcoin
61.197,66
-4,14%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Natera Inc (NTRA)

  7. Natera Inc (NTRA) News

NTRA

Natera (NTRA)

Natera Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NTRA
DatumZeitQuelleÜberschriftSymbolFirma
22/04/202414h00Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsNASDAQ:NTRANatera Inc
11/04/202414h00Business WireNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationNASDAQ:NTRANatera Inc
08/04/202414h00Business WireNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsNASDAQ:NTRANatera Inc
05/04/202413h00Business WireNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerNASDAQ:NTRANatera Inc
01/04/202414h00Business WireNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerNASDAQ:NTRANatera Inc
18/03/202412h00Business WireNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerNASDAQ:NTRANatera Inc
14/03/202413h00Business WireNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseNASDAQ:NTRANatera Inc
12/03/202413h00Business WireNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersNASDAQ:NTRANatera Inc
09/03/202402h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
07/03/202414h00Business WireNatera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanNASDAQ:NTRANatera Inc
05/03/202422h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
02/03/202402h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
01/03/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
29/02/202422h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
29/02/202417h35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
29/02/202414h00Business WireNatera to Participate in March Investor ConferencesNASDAQ:NTRANatera Inc
28/02/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTRANatera Inc
 Showing the most relevant articles for your search:NASDAQ:NTRA

Kürzlich von Ihnen besucht

TG
CBK
Commerzbank
TG
DBK
Deutsche Bank
NYSE
KO
Coca Cola
FX
EURUSD
Euro vs US Dollar
CCOM
US30
US 30
AMEX
XLE
Energy Select Sector SPDR
TG
BAYN
Bayer
NASDAQ
TSLA
Tesla
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
BASFY
BASF (QX)
PM
XAUUSD
Gold vs US Dollar
CCOM
SILVER
SILVER
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
TG
TUI1
Tui
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten